A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.
Checked against the public recordLast updated Oct 14, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Taiho Oncology, Inc.
- Interventions being studied
- Drug: TAS2940; Drug: TAS2940
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Have histologically confirmed solid cancer that is locally advanced and metastatic and available standard treatment options have been exhausted * Have adequate organ function * ECOG PS 0-1 Dose Escalation: * Have measurable or non- measurable disease per RECIST criteria v1.1 or RANO * Any solid tumor with EGFR and / or HER2 aberration Dose Expansion: * Have measurable disease per RECIST criteria v1.1 for solid tumor (excluding primary brain tumor) or RANO (for glioblastoma) * Cohort A: Non-small cell lung cancer (NSCLC) * Cohort B: HER2 positive breast cancer * Cohort C: Recurrent or refractory glioblastoma * Cohort D: Other solid tumors with EGFR or HER2 aberrations Exclusion Criteria: * Non-stable brain metastases * Have significant cardiovascular disorder * Have not recovered from prior cancer treatment * A serious illness or medical condition
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Tennessee OncologyNashville, Tennessee
- University of Texas MD Anderson Cancer CenterHouston, Texas
- CLCC Gustave RoussyVillejuif, Cedex
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 14, 2025. Always confirm current availability with the study team.